<DOC>
	<DOCNO>NCT01453569</DOCNO>
	<brief_summary>The primary purpose study determine whether sodium oligo-mannurarate capsule effective safe treatment mild moderate alzheimer ' disease , determine best therapeutic dose sodium oligo-mannurarate capsule .</brief_summary>
	<brief_title>Safety , Efficacy Dose Titration Sodium Oligo-mannurarate Capsule Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>Alzheimer 's disease know place great burden caregiver include social , psychological , physical economic aspect . Research indicate disease associate plaque tangle brain . Currently use treatment offer small symptomatic benefit . No treatment delay halt progression disease , yet , available . The investigator suppose sodium oligo-mannurarate capsule effective halt progression disease .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>At least primarily educate . Accord Probable Alzheimer disease National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) 's Criteria . 10 point ≤ Minimum MeanSquare Error ( MMSE ) ≤ 24 point . Hachinski ischemia scale ＜4 point . Hamilton depression scale ≤10 point . Should stable accompany person , least contact 2 hour per day , 4 day per week accompany person . The accompany person help patient throughout trial . Signed information consent form . Have clinical trial within 30 day trial ' start . woman pregnancy lactation . Dementia cause disease . previous nervous system disease . Abnormal laboratory result . Uncontrolled hypertension . Unstable serious disease heart , lung , liver , kidney blood . Visual auditory handicap . Significant focal lesion reveal electronic computer Xray tomography ( CT ) magnetic resonance imaging ( MRI ) one year enrollment . Alcohol abuse drug abuse . psychotic , include patient serious depression . Patients drug therapy Alzheimer disease stop . In treatment heparin , Polysaccharide sulfate , mannose ester 3 week recruitment . Investigator consider patient finish trial reason . Relatives employee investigator , staff investigate center , contract research organization sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>